Abstract
Waldenström’s macroglobulinemia (WM), also called lymphoplasmacytic lymphoma, is a rare hematologic disorder associated with a monoclonal immunoglobulin M protein (IgM) that infrequently involves the kidney. Renal manifestations are primarily glomerular abnormalities related to paraprotein deposition, but direct infiltration of the neoplastic hematopoietic cells may also be seen. Treatment is mandatory after the diagnosis of WM in symptomatic patients due primarily to complications of hyperviscosity, but no standard approach for therapy has been described. An exciting advancement in the understanding of the pathogenesis of WM is the discovery of a somatic mutation in the myeloid differentiation primary response gene 88 (MYD88) gene resulting in activation of Bruton’s tyrosine kinase and leading to survival of the neoplastic cells. This also serves as a point of therapy as a novel drug, ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, has shown great response in the treatment of WM.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Argani I, Kipkie GF (1964) Macroglobulinmic nephropathy: acute renal failure in macroglobulinemia of Waldenstroem. Am J Med 36:151–157
Audard V, Georges B, Vanhille P, Toly C, Deroure B, Fakhouri F, Cuvelier R, Belenfant X, Surin B, Aucouturier P, Mougenot B, Ronco P (2008) Renal lesions associated with IgM-secreting monoclonal proliferations: revisiting the disease spectrum. Clin J Am Soc Nephrol 3(5):1339–1349
Castillo JJ, Palomba ML, Advani R, Treon SP (2016) Ibrutinib in Waldenstrom macroglobulinemia: latest evidence and clinical experience. Ther Adv Hematol 7(4):179–186
Castro H, Valenzuela R, Ruiz P, Lenz O, Monrroy M (2008) Nephrotic syndrome and kidney failure due to immunocomplex-mediated renal damage in a patient with Waldenstrom’s macroglobulinemia: a case report. Cases J 1:3333
Crawford J, Cox EB, Cohen HJ (1985) Evaluation of hyperviscosity in monoclonal gammopathies. Am J Med 79(1):13–22
Dimopoulos MA, Alexanian R (1994) Waldenstrom’s macroglobulinemia. Blood 83(6):1452–1459
Dutcher TF, Fahey JL (1959) The histopathology of the macroglobulinemia of Waldenstrom. J Nat Cancer Inst 22:887–917
Forget BG, Squires JW, Sheldon H (1966) Waldenstrom’s macroglobulinemia with generalized amyloidosis. Arch Intern Med 118(4):363–375
Gertz MA, Kyle RA, Noel P (1993) Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenström’s macroglobulinemia. J Clin Oncol 11(5):914–920
Gnemmi V, Leleu X, Provot F, Moulonguet F, Buob D (2012) Cast nephropathy and light-chain deposition disease in Waldenström macroglobulinemia. Am J Kidney Dis 60(3):487–491
Grossman ME, Bia MJ, Goldwein MI, Hill G, Goldberg M (1977) Giant Kidneys in Waldenstrom’s macroglobulinemia. Arch Intern Med 137:1613–1615
Herrinton LJ, Weiss NS (1993) Incidence of Waldenström’s macroglobulinemia. Blood 82(10):3148–3150
Kyle RA, Anderson KC (1997) A tribute to Jan Gosta Waldenström. Blood 89(12):4245–4247
Kyle RA, Garton JP (1987) The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clin Proc 62:719–731
Lindstrom FD, Hed J, Enestrom S (1980) Renal pathology of Waldenstrom’s macroglobullinaemia with monoclonal antiglomerular antibodies and nephrotic syndrome. Clin Exp Immunol 41(2):196–204
Morel-Maroger L, Basch A, Francoise D, Verroust P, Richet G (1970) Pathology of the kidney in Waldenström’s macroglobulinemia: study of sixteen cases. N Engl J Med 283(3):123–129
Salviani C, Guido G, Serriello I, Giannakakis K, Rocca AR (2014) Renal involvement in Waldenström’s macroglobulinemia: case report and review of literature. Ren Fail 36(1):114–118
Sayed RH, Wechalekar AD, Gilbertson JA, Bass P, Mahmood S, Sachchithanantham S, Fontana M, Patel K, Whelan CJ, Lachmann HJ, Hawkins PN, Gillmore JD (2015) Natural history and outcome of light chain deposition disease. Blood 126(26):2805–2810
Shaheen SP, Talwalkar SS, Lin P, Medeiros LJ (2012) Waldenström macroglobulinemia: a review of the entity and its differential diagnosis. Adv Anat Pathol 19(1):11–27
Treon SP, Meid K, Tripsas C, Heffner LT, Eradat H, Badros AZ, Xu L, Hunte ZR, Yang G, Petterson CJ, Gustine J, Castillo JJ, Ghobrial JM, Ghobrial IM (2016) Prospective, multicenter clinical trial of everolimus as primary therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). Clin Cancer Res [Epub ahead of print]
Vijay A, Gertz MA (2007) Waldenstrom macroglobulinemia. Blood 109(12):5096–5103
Vos JM, Gustine J, Rennke HG, Hunter Z, Manning RJ, Dubeau TE, Meid K, Minnema MC, Kersten MJ, Treon SP, Castillo JJ (2016) Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes. Br J Haematol 175(4):623–630
Yang G, Zhou Y, Liu X, Xu L, Cao Y, Manning RJ, Patterson CJ, Buhrlage SJ, Gray N, Tai YT, Anderson KC, Hunter ZR, Treon SP (2013) A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia. Blood 122(7):1222–32
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this entry
Cite this entry
Kapp, M.E., Vischini, G., Fogo, A.B. (2017). Waldenstrom Macroglobulinemia. In: Trachtman, H., Hogan, J., Herlitz, L., Lerma, E. (eds) Glomerulonephritis. Springer, Cham. https://doi.org/10.1007/978-3-319-27334-1_37-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-27334-1_37-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-27334-1
Online ISBN: 978-3-319-27334-1
eBook Packages: Springer Reference MedicineReference Module Medicine